EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer

被引:86
作者
Clancy, JL
Henderson, MJ
Russell, AJ
Anderson, DW
Bova, RJ
Campbell, IG
Choong, DYH
Macdonald, GA
Mann, GJ
Nolan, T
Brady, G
Olopade, OI
Woollatt, E
Davies, MJ
Segara, D
Hacker, NF
Henshall, SM
Sutherland, RL
Watts, CKW
机构
[1] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia
[2] NIDCD, Mol Genet Lab, NIH, Rockville, MD USA
[3] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
[4] Univ Queensland, Populat & Clin Sci Div, Queensland Inst Med Res, Brisbane, Qld, Australia
[5] Univ Queensland, Dept Med, Brisbane, Qld, Australia
[6] Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia
[7] Univ Manchester, Sch Biol Sci, Manchester, Lancs, England
[8] Univ Chicago, Med Ctr, Ctr Med Genet, Chicago, IL 60637 USA
[9] Womens & Childrens Hosp, Ctr Med Genet, Adelaide, SA, Australia
[10] Royal Hosp Women, Gynaecol Canc Ctr, Randwick, NSW 2031, Australia
基金
英国医学研究理事会;
关键词
allelic imbalance; amplification; human neoplasms; gene expression; mutation;
D O I
10.1038/sj.onc.1206775
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
EDD (E3 isolated by differential display), located at chromosome 8q22.3, is the human orthologue of the Drosophila melanogaster tumour suppressor gene 'hyperplastic discs' and encodes a HECT domain E3 ubiquitin protein-ligase. To investigate the possible involvement of EDD in human cancer, several cancers from diverse tissue sites were analysed for allelic gain or loss (allelic imbalance, AI) at the EDD locus using an EDD-specific microsatellite, CEDD, and other polymorphic microsatellites mapped in the vicinity of the 8q22.3 locus. Of 143 cancers studied, 38 had AI at CEDD (42% of 90 informative cases). In 14 of these cases, discrete regions of imbalance encompassing 8q22.3 were present, while the remainder had more extensive 8q aberrations. AI of CEDD was most frequent in ovarian cancer (22/47 informative cases, 47%), particularly in the serous subtype (16/22, 73%), but was rare in benign and borderline ovarian tumours. AI was also common in breast cancer (31%), hepatocellular carcinoma (46%), squamous cell carcinoma of the tongue (50%) and metastatic melanoma (18%). AI is likely to represent amplification of the EDD gene locus rather than loss of heterozygosity, as quantitative RT-PCR and immunohistochemistry showed that EDD mRNA and protein are frequently overexpressed in breast and ovarian cancers, while among breast cancer cell lines EDD overexpression and increased gene copy number were correlated. These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression.
引用
收藏
页码:5070 / 5081
页数:12
相关论文
共 57 条
[1]   Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21 [J].
Aita, VM ;
Liang, XH ;
Murty, VVVS ;
Pincus, DL ;
Yu, WP ;
Cayanis, E ;
Kalachikov, S ;
Gilliam, TC ;
Levine, B .
GENOMICS, 1999, 59 (01) :59-65
[2]  
Al-Taher A, 2000, YEAST, V17, P201, DOI 10.1002/1097-0061(20000930)17:3<201::AID-YEA30>3.0.CO
[3]  
2-R
[4]  
Balleine RL, 2000, GENE CHROMOSOME CANC, V29, P48, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1005>3.0.CO
[5]  
2-O
[6]  
Bova RJ, 1999, CLIN CANCER RES, V5, P2810
[7]  
BUCKLEY MF, 1993, ONCOGENE, V8, P2127
[8]   Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs [J].
Callaghan, MJ ;
Russell, AJ ;
Woollatt, E ;
Sutherland, GR ;
Sutherland, RL ;
Watts, CKW .
ONCOGENE, 1998, 17 (26) :3479-3491
[9]  
CALLEN DF, 1990, ANN GENET-PARIS, V33, P219
[10]   A NOVEL GENE ENCODING A B-BOX PROTEIN WITHIN THE BRCA1 REGION AT 17Q21.1 [J].
CAMPBELL, IG ;
NICOLAI, HM ;
FOULKES, WD ;
SENGER, G ;
STAMP, GW ;
ALLAN, G ;
BOYER, C ;
JONES, K ;
BAST, RC ;
SOLOMON, E ;
TROWSDALE, J ;
BLACK, DM .
HUMAN MOLECULAR GENETICS, 1994, 3 (04) :589-594